Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sotrovimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Demographics and outcomes of initial phase of COVID-19 Medicines Delivery Units across 4 UK centres during peak B1.1.529 omicron epidemic: a service evaluation

Brown et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac527
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Hospitalization -258% Improvement Relative Risk Sotrovimab for COVID-19  Brown et al.  EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 408 patients in the United Kingdom Higher hospitalization with sotrovimab (not stat. sig., p=0.15) c19early.org Brown et al., Open Forum Infectious Di.., Oct 2022 Favors sotrovimab Favors control
Sotrovimab for COVID-19
40th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.0017 from 22 studies, recognized in 38 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 186 patients in the UK treated with sotrovimab, and 222 eligible but declining treatment, showing no significant difference in hospitalization. No group details are provided and the results are subject to confounding by indication.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.11-3, BA.4, BA.54, XBB.1.9.3, XBB.1.5.24, XBB.2.9, CH.1.15, and no efficacy for BA.26, ХВВ.1.9.1, XBB.1.16, BQ.1.1.45, and CL.15. US EUA has been revoked.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; significant unadjusted confounding possible.
Study covers sotrovimab and molnupiravir.
risk of hospitalization, 258.1% higher, RR 3.58, p = 0.15, treatment 6 of 186 (3.2%), control 2 of 222 (0.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Brown et al., 6 Oct 2022, retrospective, United Kingdom, peer-reviewed, 17 authors. Contact: michael.marks@lshtm.ac.uk, anna.goodman@gstt.nhs.uk.
This PaperSotrovimabAll
M Brown, J Gahir, Simpson, K Elgizouli, 10 Marks, Michael Marks, Anna Goodman
doi:10.1093/ofid/ofac527/6750023
Title Demographics and outcomes of initial phase of COVID-19 Medicines Delivery Units across 4 UK centres during peak B1.1.529 omicron epidemic: a service evaluation.
Funding No specific funding for this work. MM is supported by NIHR and the EDCTP. Conflict of Interest The authors have no conflicts of interest to declare
References
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Carr, Wu, Harvey, Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients, The Lancet
Cheng, Mok, Leung, Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination, Nat Med
Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
Gupta, Gonzalez-Rojas, Juarez, Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab, N Engl J Med
Menni, Valdes, Polidori, Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study, The Lancet
Nyberg, Ferguson, Nash, Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study, The Lancet
Planas, Saunders, Maes, Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, Nature
{ 'indexed': {'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T20:43:50Z', 'timestamp': 1665089030312}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T00:00:00Z', 'timestamp': 1665014400000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Introduction</jats:title>\n' ' <jats:p>COVID-19 Medicine Delivery Units (CMDU) were established in late ' 'December 2021 to deliver early antiviral therapy to patients classified as at risk with the ' 'aim of preventing hospitalisation.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We performed a service evaluation at four CMDUs in England. We ' 'assessed demographics and triage outcomes of CMDU referral, uptake of antiviral therapy and ' 'the rate of subsequent hospitalisations within two weeks of CMDU referral.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Over a three week period 4,788 patients were referred and 3,989 ' 'were ultimately assessed by a CMDU. Overall, 832 of the patients referred (17%) were judged ' 'eligible for treatment and 628 (13%) were ultimately prescribed an antiviral agent. The ' 'overall rate of admission within 14 days was 1%. Patients who were admitted were ' 'significantly older than those who did not require hospitalisation. Of patients prescribed ' 'molnupiravir and sotrovimab 1.8% and 3.2% were admitted respectively.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>There were a high volume of referrals to CMDU service during the ' 'the initial surge of the Omicron wave in the UK. A minority of patients were judged to be ' 'eligible for therapy. In a highly vaccinated population, the overall hospitalisation rate was ' 'low.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/ofid/ofac527', 'type': 'journal-article', 'created': {'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T20:13:46Z', 'timestamp': 1665087226000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Demographics and outcomes of initial phase of COVID-19 Medicines Delivery Units across 4 UK ' 'centres during peak B1.1.529 omicron epidemic: a service evaluation.', 'prefix': '10.1093', 'author': [ { 'given': 'M', 'family': 'Brown', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Infection, University College London Hospitals NHS ' 'Foundation Trust , London , UK'}, { 'name': 'Clinical Research Dept, London School of Hygiene & Tropical ' 'Medicine , London , UK'}]}, { 'given': 'J', 'family': 'Saund', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infection, University College London Hospitals NHS ' 'Foundation Trust , London , UK'}]}, { 'given': 'A', 'family': 'Qureshi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infection, Guys and St Thomas’s NHS Foundation ' 'Trust , London , UK'}, { 'name': 'South East London Covid Prevention and Intervention Service, ' 'Guys and St Thomas’s NHS Foundation Trust , London , UK'}]}, { 'given': 'M', 'family': 'Plowright', 'sequence': 'additional', 'affiliation': [ { 'name': 'Dept of Infectious Diseases & Tropical Medicine, Sheffield ' 'Teaching Hospitals NHS Foundation Trust , Sheffield , UK'}, { 'name': 'Dept Infection, Immunity & Cardiovascular Disease, University of ' 'Sheffield , UK'}]}, { 'given': 'K', 'family': 'Drury', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Research Group, Hull University Teaching Hospitals NHS ' 'Foundation Trust , Hull , UK'}]}, { 'given': 'J', 'family': 'Gahir', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infection, University College London Hospitals NHS ' 'Foundation Trust , London , UK'}]}, { 'given': 'T', 'family': 'Simpson', 'sequence': 'additional', 'affiliation': [{'name': 'Lewisham Hospital , London , UK'}]}, { 'given': 'T', 'family': 'Newman', 'sequence': 'additional', 'affiliation': [ { 'name': 'Dept of Infectious Diseases & Tropical Medicine, Sheffield ' 'Teaching Hospitals NHS Foundation Trust , Sheffield , UK'}, { 'name': 'Dept Infection, Immunity & Cardiovascular Disease, University of ' 'Sheffield , UK'}]}, { 'given': 'K', 'family': 'Adams', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Research Group, Hull University Teaching Hospitals NHS ' 'Foundation Trust , Hull , UK'}]}, { 'given': 'J', 'family': 'Galloway', 'sequence': 'additional', 'affiliation': [{'name': 'Centre for Rheumatic Disease, Kings College London , UK'}]}, { 'given': 'K', 'family': 'Durairaj', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infection, Guys and St Thomas’s NHS Foundation ' 'Trust , London , UK'}, { 'name': 'South East London Covid Prevention and Intervention Service, ' 'Guys and St Thomas’s NHS Foundation Trust , London , UK'}]}, { 'given': 'K', 'family': 'Elgizouli', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Research Group, Hull University Teaching Hospitals NHS ' 'Foundation Trust , Hull , UK'}]}, { 'given': 'T', 'family': 'Rampling', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infection, University College London Hospitals NHS ' 'Foundation Trust , London , UK'}]}, { 'given': 'J', 'family': 'Cole', 'sequence': 'additional', 'affiliation': [ { 'name': 'Dept of Infectious Diseases & Tropical Medicine, Sheffield ' 'Teaching Hospitals NHS Foundation Trust , Sheffield , UK'}, { 'name': 'Dept Infection, Immunity & Cardiovascular Disease, University of ' 'Sheffield , UK'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6413-919X', 'authenticated-orcid': False, 'given': 'N', 'family': 'Easom', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Research Group, Hull University Teaching Hospitals NHS ' 'Foundation Trust , Hull , UK'}]}, { 'given': 'A', 'family': 'Goodman', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infection, Guys and St Thomas’s NHS Foundation ' 'Trust , London , UK'}, { 'name': 'South East London Covid Prevention and Intervention Service, ' 'Guys and St Thomas’s NHS Foundation Trust , London , UK'}, { 'name': 'MRC Clinical Trials Unit, University College London , London , ' 'UK'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7585-4743', 'authenticated-orcid': False, 'given': 'M', 'family': 'Marks', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infection, University College London Hospitals NHS ' 'Foundation Trust , London , UK'}, { 'name': 'Clinical Research Dept, London School of Hygiene & Tropical ' 'Medicine , London , UK'}, { 'name': 'Division of Infection and Immunity, University College London , ' 'London , UK'}]}], 'member': '286', 'published-online': {'date-parts': [[2022, 10, 6]]}, 'container-title': 'Open Forum Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac527/46354871/ofac527.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac527/46354871/ofac527.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T20:13:46Z', 'timestamp': 1665087226000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac527/6750023'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10, 6]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/ofid/ofac527', 'relation': {}, 'ISSN': ['2328-8957'], 'subject': ['Infectious Diseases', 'Oncology'], 'published': {'date-parts': [[2022, 10, 6]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit